Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11308431 | 0.90 | CYP3A4 (0.41) | CYP3A4LMNAMEN1KMT2AMAPT | |
| SCHEMBL2807615 | 0.90 | CYP3A4 (0.41) | CYP3A4LMNAMEN1KMT2AMAPT | |
| Phthalic Acid SCHEMBL8918784 | 0.81 | TSHR (0.44) | CYP3A4LMNAMEN1KMT2AMAPT | |
| SCHEMBL291627 | 0.81 | KDM4E (0.47) | MEN1KMT2AMAPTKDM4ETSHR | |
| Aspirin SCHEMBL10787619 | 0.81 | PTGS2 (0.50) | CYP3A4LMNAMEN1KMT2AMAPT | |
| Aspirin SCHEMBL10792710 | 0.76 | PTGS2 (0.50) | CYP3A4LMNAMEN1KMT2AMAPT | |
| Salicylic Acid SCHEMBL2810943 | 0.76 | KDM4E (0.59) | CYP3A4LMNAKMT2AMAPTKDM4E | |
| Salicylic Acid SCHEMBL406693 | 0.76 | KDM4E (0.59) | CYP3A4LMNAKMT2AMAPTKDM4E | |
| Phenol SCHEMBL967203 | 0.75 | MAPT (0.39) | MEN1KMT2AMAPTKDM4ETSHR | |
| Aspirin SCHEMBL10789783 | 0.72 | PTGS2 (0.53) | LMNAMEN1KMT2AKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207416-B1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | IMERYS FILTRATION MINERALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20100239679-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | WORLD MINERALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
| US-4219602-A | Electrically conductive/antistatic sheeting | HERCULITE PROTECTIVE FABRICS CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | ENPP1, ENPP3, SMPD1 | CYP3A4 2428/4885LMNA 3199/4885MEN1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.